Peroxisome Proliferator-Activated Receptor γ Pathway Targeting in Carcinogenesis: Implications for Chemoprevention

The peroxisome proliferator-activated receptor (PPAR) γ is one member of the nuclear receptor superfamily that contains in excess of 80 described receptors. PPARγ activators are a diverse group of agents that range from endogenous fatty acids or derivatives (linolenic, linoleic, and 15-deoxy-Δ12,14-prostaglandin J2) to Food and Drug Administration-approved thiazolidinedione drugs [pioglitazone (Actos) and rosiglitazone (Avandia)] for the treatment of diabetes. Once activated, PPARγ will preferentially bind with retinoid X receptor α and signal antiproliferative, antiangiogenic, and prodifferentiation pathways in several tissue types, thus making it a highly useful target for down-regulation of carcinogenesis. Although PPAR-γ activators show many anticancer effects on cell lines, their advancement into human advanced cancer clinical trials has met with limited success. This article will review translational findings in PPARγ activation and targeting in carcinogenesis prevention as they relate to the potential use of PPARγ activators clinically as cancer chemoprevention strategies.

[1]  J. G. Alvarez,et al.  Activators of the nuclear receptor PPARγ enhance colon polyp formation , 1998, Nature Medicine.

[2]  A. Gill,et al.  Detection of the PAX8-PPARγ Fusion Oncogene in Both Follicular Thyroid Carcinomas and Adenomas , 2003 .

[3]  Eric Small,et al.  Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate‐specific antigen level after radical prostatectomy and/or radiation therapy , 2004, Cancer.

[4]  R. Lotan.  Retinoids and their receptors in modulation of differentiation, development, and prevention of head and neck cancers. , 1996, Anticancer research.

[5]  R. Glazer,et al.  Peroxisome Proliferator-Activated Receptor δ and γ Agonists Differentially Alter Tumor Differentiation and Progression during Mammary Carcinogenesis , 2005 .

[6]  L. Hensley,et al.  Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions , 2004, Expert Reviews in Molecular Medicine.

[7]  J. Auwerx,et al.  Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator–activated receptor-γ , 2005, The Journal of experimental medicine.

[8]  V. Iyer,et al.  CARM1 promotes adipocyte differentiation by coactivating PPARγ , 2008, EMBO reports.

[9]  C. Datz,et al.  Peroxisome proliferator-activated receptor gamma is induced during differentiation of colon epithelium cells. , 1999, The Journal of endocrinology.

[10]  R. Kucherlapati,et al.  Peroxisome proliferator‐activated receptor γ agonist troglitazone induces colon tumors in normal C57BL/6J mice and enhances colonic carcinogenesis in Apc1638 N/+ Mlh1+/− double mutant mice , 2005, International journal of cancer.

[11]  B. Spiegelman,et al.  PAX8-PPARγ1 Fusion in Oncogene Human Thyroid Carcinoma , 2000 .

[12]  J. Girard,et al.  Phosphorylation of PPARs: from molecular characterization to physiological relevance. , 2005, Biochimie.

[13]  I. Cho,et al.  Transactivation of the PPAR-Responsive Enhancer Module in Chemopreventive Glutathione S-Transferase Gene by the Peroxisome Proliferator-Activated Receptor-γ and Retinoid X Receptor Heterodimer , 2004, Cancer Research.

[14]  N. Arber,et al.  Chemoprevention of colorectal cancer: two steps forward, one step back? , 2006, Future oncology.

[15]  I. Weinstein,et al.  Synergistic effects of RXR&agr; and PPAR&ggr; ligands to inhibit growth in human colon cancer cells—phosphorylated RXR&agr; is a critical target for colon cancer management , 2007, Gut.

[16]  L. Altucci,et al.  Retinoids: potential in cancer prevention and therapy , 2004, Expert Reviews in Molecular Medicine.

[17]  E. Siegel,et al.  Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  T. Willson,et al.  Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[19]  P. Plourde,et al.  Duration of tamoxifen therapy and occurrence of endometrial cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  B. Spiegelman,et al.  Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[21]  M. Brady,et al.  The Nuclear Receptor Corepressors NCoR and SMRT Decrease Peroxisome Proliferator-activated Receptor γ Transcriptional Activity and Repress 3T3-L1 Adipogenesis* , 2005, Journal of Biological Chemistry.

[22]  S. Fischer,et al.  The effect of PPARγ ligands on UV‐ or chemically‐induced carcinogenesis in mouse skin , 2005, Molecular carcinogenesis.

[23]  B. Spiegelman.  PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. , 1998, Diabetes.

[24]  J. Reddy,et al.  Carcinogenesis by hepatic peroxisome proliferators: evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans. , 1983, Critical reviews in toxicology.

[25]  Takuji Tanaka,et al.  9trans,11trans Conjugated Linoleic Acid Inhibits the Development of Azoxymethane-Induced Colonic Aberrant Crypt Foci in Rats , 2007, Nutrition and cancer.

[26]  M. Sporn,et al.  Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  U. Vogel,et al.  Peroxisome proliferator-activated [corrected] receptor-gamma2 [corrected] Pro12Ala, interaction with alcohol intake and NSAID use, in relation to risk of breast cancer in a prospective study of Danes. , 2006, Carcinogenesis.

[28]  K. Kinzler,et al.  PPARδ Is an APC-Regulated Target of Nonsteroidal Anti-Inflammatory Drugs , 1999, Cell.

[29]  S. Lippman,et al.  Pilot Randomized Phase II Study of Celecoxib in Oral Premalignant Lesions , 2008, Clinical Cancer Research.

[30]  C. J. Chen,et al.  PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. , 2000, Science.

[31]  B. Spiegelman,et al.  Use of the Peroxisome Proliferator-Activated Receptor (PPAR) γ Ligand Troglitazone as Treatment for Refractory Breast Cancer: A Phase II Study , 2003, Breast Cancer Research and Treatment.

[32]  Takuji Tanaka,et al.  Dietary seed oil rich in conjugated linolenic acid from bitter melon inhibits azoxymethane‐induced rat colon carcinogenesis through elevation of colonic PPARγ expression and alteration of lipid composition , 2004, International journal of cancer.

[33]  Sui Huang,et al.  PPARγ as a therapeutic target for tumor angiogenesis and metastasis , 2005 .

[34]  G. Demetri,et al.  Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-g ligand troglitazone in patients with liposarcoma (nuclear receptorsysarcomaydrug developmentyoncologyyantineoplastic) , 1999 .

[35]  Erland Erdmann,et al.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.

[36]  J. Berger,et al.  The mechanisms of action of PPARs. , 2002, Annual review of medicine.

[37]  Sheue-yann Cheng,et al.  Thyroid hormone receptor β mutants: Dominant negative regulators of peroxisome proliferator-activated receptor γ action , 2005 .

[38]  J. Peters,et al.  Peroxisome Proliferator-activated Receptor-β/δ Inhibits Epidermal Cell Proliferation by Down-regulation of Kinase Activity* , 2005, Journal of Biological Chemistry.

[39]  Kazuhiro Yoshida,et al.  Inhibitory effect of linoleic acid on transformation of IEC6 intestinal cells by in vitro azoxymethane treatment , 2006, International journal of cancer.

[40]  M. Notarnicola,et al.  Peroxisome proliferator-activated receptor gamma and spermidine/spermine N1-acetyltransferase gene expressions are significantly correlated in human colorectal cancer , 2006, BMC Cancer.

[41]  J. V. Vanden Heuvel,et al.  Modulation of PPAR activity via phosphorylation. , 2007, Biochimica et biophysica acta.

[42]  Hirokazu Takahashi,et al.  5-Aminosalicylic Acid Given in the Remission Stage of Colitis Suppresses Colitis-Associated Cancer in a Mouse Colitis Model , 2007, Clinical Cancer Research.

[43]  E. Williamson,et al.  A ligand of peroxisome proliferator-activated receptor gamma, retinoids, and prevention of preneoplastic mammary lesions. , 2000, Journal of the National Cancer Institute.

[44]  M. Sporn,et al.  A New Ligand for the Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ), GW7845, Inhibits Rat Mammary Carcinogenesis , 1999 .

[45]  Robert Riddell,et al.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. , 2005, The New England journal of medicine.

[46]  J. Southgate,et al.  Activation of peroxisome proliferator-activated receptor-gamma reverses squamous metaplasia and induces transitional differentiation in normal human urothelial cells. , 2004, The American journal of pathology.

[47]  K. Miyashita,et al.  Troglitazone and 9cis,11trans,13trans-Conjugated Linolenic Acid: Comparison of Their Antiproliferative and Apoptosis-Inducing Effects on Different Colon Cancer Cell Lines , 2006, Chemotherapy.

[48]  山崎 健路.  Synergistic effects of RXRα and PPARγ ligands to inhibit growth in human colon cancer cells-phosphorylated RXRα is a critical target for colon cancer management , 2008 .

[49]  John Dormandy,et al.  The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. , 2004, Diabetes care.

[50]  Lucia Altucci,et al.  The promise of retinoids to fight against cancer , 2001, Nature Reviews Cancer.

[51]  Samuel M. Cohen,et al.  Urothelial Carcinogenesis in the Urinary Bladder of Male Rats Treated with Muraglitazar, a PPARα/γ Agonist: Evidence for Urolithiasis as the Inciting Event in the Mode of Action , 2006, Toxicologic pathology.

[52]  S. Nissen,et al.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.

[53]  K. Mafune,et al.  Chemopreventive effect of peroxisome proliferator-activated receptor gamma on gastric carcinogenesis in mice. , 2005, Cancer research.

[54]  David Y. Lai,et al.  PPARα Agonist-Induced Rodent Tumors: Modes of Action and Human Relevance , 2003 .

[55]  R. Lotan.  Retinoids and chemoprevention of aerodigestive tract cancers , 1997, Cancer and Metastasis Reviews.

[56]  J. Southgate,et al.  Role of PPAR γ and EGFR signalling in the urothelial terminal differentiation programme , 2004, Journal of Cell Science.

[57]  Edward S. Kim,et al.  Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. , 2006, Journal of the National Cancer Institute.

[58]  Reddy Jk,et al.  Carcinogenesis by Hepatic Peroxisome Proliferators: Evaluation of the Risk of Hypolipidemic Drugs and Industrial Plasticizers to Humans , 1983 .

[59]  K. Umesono,et al.  Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[60]  I. Issemann,et al.  The molecular mechanism of peroxisome proliferator action: a model for species differences and mechanistic risk assessment. , 1992, Toxicology letters.

[61]  K. Umesono,et al.  The nuclear receptor superfamily: The second decade , 1995, Cell.

[62]  J. Reichrath,et al.  Present concepts and future outlook: Function of peroxisome proliferator‐activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer , 2007, Journal of cellular physiology.

[63]  R. Lotan,et al.  Suppression of retinoic acid receptor beta in non-small-cell lung cancer in vivo: implications for lung cancer development. , 1997, Journal of the National Cancer Institute.

[64]  P. Puigserver,et al.  Transcriptional regulation of adipogenesis. , 2000, Genes & development.

[65]  R. Lotan.  Retinoids in cancer chemoprevention , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[66]  Mingui Fu,et al.  A Nuclear Receptor Atlas: 3T3-L1 adipogenesis. , 2005, Molecular endocrinology.

[67]  J. Phang,et al.  Proline Oxidase, a Proapoptotic Gene, Is Induced by Troglitazone , 2006, Journal of Biological Chemistry.

[68]  R. Evans,et al.  The Nuclear Receptor Superfamily: a Rosetta Stone for Physiology , 1985 .

[69]  M. Sporn,et al.  Treatment and Prevention of Intraepithelial Neoplasia: An Important Target for Accelerated New Agent Development: Recommendations of the American Association for Cancer Research Task Force on the Treatment and Prevention of Intraepithelial Neoplasia , 2002 .

[70]  Amy Y. M. Au,et al.  PAX8-Peroxisome Proliferator-Activated Receptor γ (PPARγ) Disrupts Normal PAX8 or PPARγ Transcriptional Function and Stimulates Follicular Thyroid Cell Growth , 2006 .

[71]  Takuji Tanaka,et al.  An animal model for the rapid induction of tongue neoplasms in human c-Ha-ras proto-oncogene transgenic rats by 4-nitroquinoline 1-oxide: its potential use for preclinical chemoprevention studies. , 2006, Carcinogenesis.

[72]  R. Lotan,et al.  Overexpressed Activated Retinoid X Receptors Can Mediate Growth Inhibitory Effects of Retinoids in Human Carcinoma Cells* , 1998, The Journal of Biological Chemistry.

[73]  Yingying Liu,et al.  Inhibition of Rat Mammary Gland Carcinogenesis by Simultaneous Targeting of Cyclooxygenase-2 and Peroxisome Proliferator-activated Receptor γ , 2004, Cancer Research.

[74]  B. Spiegelman,et al.  Molecular regulation of adipogenesis. , 2000, Annual review of cell and developmental biology.

[75]  S. Fischer,et al.  Troglitazone inhibits cyclin D1 expression and cell cycling independently of PPARgamma in normal mouse skin keratinocytes. , 2004, The Journal of investigative dermatology.